Frances Vila-Hereter

Frances Vila-Hereter

Auto-generated profile, based on publicly available information

Frances Vila-Hereter

Centers for Disease Control and Prevention (CDC), San Juan, PR, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
FMFreddy A. Medina
Freddy A. Medina
FVFrances Vila
Frances Vila
LALaura E. Adams
Laura E. Adams
JCJaime Cardona
Jaime Cardona
JCJessica Carrion
Jessica Carrion
JMJorge L. Muñoz-Jordán
Jorge L. Muñoz-Jordán
The Advisory Committee on Immunization Practices (ACIP) recommended that dengue pre-vaccination screening tests for Dengvaxia administration have at least 98% specificity and 75% sensitivity. This study evaluates the performance of commercial anti-DENV IgG tests to identify tests that could be used for pre-vaccination screening. First, for seven tests, we evaluated sensitivity and specificity in early convalescent dengue virus (DENV) infection, using 44 samples collected 7–30 days after symptom onset and confirmed by RT-PCR. Next, for the five best-performing tests and two additional tests (with and without an external test reader) that became available later, we evaluated performance to detect past dengue infection among a panel of 44 specimens collected in 2018–2019 from healthy 9- to 16-year-old children from Puerto Rico. Finally, a full-scale evaluation was done with the four best-performing tests using 400 specimens from the same population. We used virus focus reduction neutralization test and an in-house DENV IgG ELISA as reference standards. Of seven tests, five showed ≥75% sensitivity in detecting anti-DENV IgG in early convalescent specimens with low cross-reactivity to the Zika virus. For the detection of previous DENV infections, the tests with the highest performance were the Euroimmun NS1 IgG ELISA (sensitivity 84.5%, specificity 97.1%) and CTK Dengue IgG rapid test R0065C with the test reader (sensitivity 76.2% specificity 98.1%). There are IgG tests available that can be used to accurately classify individuals with previous DENV infection as eligible for dengue vaccination to support safe vaccine implementation. IMPORTANCE: The Advisory Committee on Immunization Practices (ACIP) has set forth recommendations that dengue pre-vaccination screening tests must exhibit at least 98% specificity and 75% sensitivity. Our research rigorously assesses the performance of various commercial tests against these benchmarks using well-characterized specimens from Puerto Rico. The findings from our study are particularly relevant given FDA approval and ACIP recommendation of Sanofi Pasteur’s Dengvaxia vaccine, highlighting the need for accurate pre-vaccination screening tools.

23 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HDHans Desale
Hans Desale
FJForrest K Jones
Forrest K Jones
FVFrances Vila-Hereter
Frances Vila-Hereter
JCJessica Carrion
Jessica Carrion
MBManuela Beltran
Manuela Beltran
FMFreddy A. Medina
Freddy A. Medina
Dengue is an emerging public health threat in the United States, and currently, no FDA-approved rapid diagnostic test (RDT) is available. A reliable RDT could support timely clinical management and outbreak response. We evaluated nine commercially available dengue RDTs using 197 stored serum samples: 99 from acute laboratory-confirmed dengue cases, 88 negative by RT-PCR, IgM ELISA, and NS1 ELISA, and 10 from acute confirmed Zika cases. Test performance varied, with sensitivity ranging from 36%–82% and specificity from 78%–100%. The CTK Biotech and Artron tests showed the highest sensitivity (80% and 82%, respectively), but only CTK Biotech maintained high specificity (98%). Cross-reactivity with Zika virus was low (0%–20%). These findings suggest that RDTs could enhance dengue detection in clinical settings, though further validation under field conditions is warranted, and some of these tests may be suitable for regulatory approval, which could lead to broader availability and use.